In vitro evaluation of an intraluminal solution to attenuate effects of ischemia and reperfusion in the small intestine of horses

Effects of liposomal-curcumin on five opportunistic bacterial strains found in the equine hindgut - preliminary study

Background

The horse intestinal tract is sensitive and contains a highly complex microbial population. A shift in the microbial population can lead to various issues such as inflammation and colic. The use of nutraceuticals in the equine industry is on the rise and curcumin is thought to possess antimicrobial properties that may help to minimize the proliferation of opportunistic bacteria.

Methods

Four cecally-cannulated horses were utilized to determine the optimal dose of liposomal-curcumin (LIPC) on reducing Streptococcus bovis/equinus complex (SBEC), Escherichia coli K-12, Escherichia coli general, Clostridium difficile, and Clostridium perfringens in the equine hindgut without adversely affecting cecal characteristics. In the first study cecal fluid was collected from each horse and composited for an in vitro, 24 h batch culture to examine LIPC at four different dosages (15, 20, 25, and 30 g) in a completely randomized design. A subsequent in vivo 4 × 4 Latin square design study was conducted to evaluate no LIPC (control, CON) or LIPC dosed at 15, 25, and 35 g per day (dosages determined from in vitro results) for 9 days on the efficacy of LIPC on selected bacterial strains, pH, and volatile fatty acids. Each period was 14 days with 9 d for acclimation and 5 d withdrawal period.

Results

In the in vitro study dosage had no effect (P ≥ 0.42) on Clostridium strains, but as the dose increased SBEC concentrations increased (P = 0.001). Concentrations of the E. coli strain varied with dose. In vivo, LIPC’s antimicrobial properties, at 15 g, significantly decreased (P = 0.02) SBEC when compared to 25 and 35 g dosages. C. perfringens decreased linearly (P = 0.03) as LIPC dose increased. Butyrate decreased linearly (P = 0.01) as LIPC dose increased.

Conclusion

Further studies should be conducted with a longer dosing period to examine the antimicrobial properties of curcumin without adversely affecting cecal characteristics.

Oxidative stress

Oxidative stress refers to the cellular injury and pathologic change that occurs when there is an imbalance favoring oxidants over antioxidants within a living organism. In human medicine, oxidative stress has been implicated in numerous disease processes, which has led to further research into the clinical benefits and efficacy of antioxidant therapy. The evaluation of oxidative stress in the horse has been limited primarily to ischemia-reperfusion injury of the gastrointestinal tract, recurrent airway obstruction, exercise, osteoarthritis, equine motor neuron disease, and pituitary pars intermedia dysfunction. Each of these is examined in this review in terms of the current evidence for oxidative stress as well as the evidence for current antioxidant therapy in equine medicine and the potential of future research and therapies. Oxidative stress research is currently an emerging field with relevance to the equine critical patient.

Treatment of gastrointestinal ischemic injury

Ischemic injury is one of the most important causes of mortality in equine veterinary medicine. Although treatment of reperfusion injury has been attempted in a number of experimental trials to reduce the level of injury subsequent to an ischemic episode, this research has not resulted in the development of useful clinical treatments. Nevertheless, recent studies assessing intraluminal application of solutions containing antioxidants, nutrients, and vasodilators are promising. Furthermore, focusing on improving mucosal recovery after an ischemic event may provide an alternative method of reducing mortality. Potential treatments include administration of basement membrane components like hyaluronic acid, gut-specific nutrients like glutamine, and early return to feeding to stimulate endogenous repair mechanisms. Finally, recent studies evaluating NSAIDs have revealed the potential of flunixin meglumine to retard the mucosal repair process, indicating the need for judicious use of this drug.